AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 181 min read$KMTS

Webster Brian Daniel sold $412K of KMTS

Webster Brian Daniel (See Remarks) sold 15,000 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at $27.48 ($0.41M total) on 2026-08-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Webster Brian Daniel
Published Aug 18, 2026, 11:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 11:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$KMTS
Neutral
high confidence
Mentioned
$KMTS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KMTSNeutralLow
01

Why it matters

The disclosed open-market sale reduces insider holdings but, due to the stated 10b5-1 pre-arranged plan, it is typically treated as lower-signal than discretionary selling.

02

Market read

Traders may briefly reassess sentiment around KMTS, but the event is primarily administrative and not a new business catalyst.

03

What to watch

The filing does not disclose any new KMTS fundamentals; the only actionable element is monitoring for future non-10b5-1 insider transactions.

Relevance 3/10Novelty 2/10Timing: filed 2026-08-18, sale dated 2026-08-17

Background

This is an SEC Form 4 insider transaction disclosure for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS).

Company-level read

Ticker impact

$KMTSNeutralHigh confidence
Context

Form 4 shows officer/director Webster Brian Daniel sold 15,000 KMTS shares at $27.4787 on 2026-08-17 under a 10b5-1 plan.

Expected impact

Low near-term impact; any effect is likely sentiment-only and quickly absorbed.

Evidence & confidence

The filing is a scheduled open-market sale under a pre-arranged 10b5-1 plan, with no accompanying company-specific operational or financial disclosure.

Market effects

Sector

No clear sector read-through from a single 10b5-1 sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations, so traders may ignore it.

Key entities

  • issuer
    KMTS

    Kestra Medical Technologies, Ltd., the company whose insider sale is disclosed.

  • insider
    Webster Brian Daniel

    Officer and director who sold 15,000 shares via an open-market transaction under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KMTS insider trading history →

Related articles

SEP 16
$KMTSHighAI 8/10

Kestra Medical Technologies Signals Profitable Growth Path

Kestra Medical Technologies (KMTS) reported Q1 revenue of $31M, up 60% YoY, with gross margin at 56.5%, up from 45.7% YoY. The company raised 2027 revenue guidance to $141M and expects profitability within a few years. Management highlighted strong growth drivers, including market expansion and automation.

tipranks.com3 min
SEP 15
$KMTSMed

Kestra (KMTS) Q1 2027 Earnings Call Transcript

Kestra Medical Technologies (KMTS) reported Q1 2027 revenue of $31.0M, up 60% YoY, and raised full-year guidance to $141M. Gross margin increased to 56.5%, driven by volume leverage and cost improvements. The company invested heavily in R&D and commercial expansion, resulting in a GAAP net loss of $44.1M. Management highlighted market share gains and expanded payer coverage for non-ischemic patients.

aol.com2 min
SEP 15
$KMTSMedAI 8/10

Kestra Medical Technologies Ltd (KMTS) (Q1 2027) Earnings Call Highlights: Revenue Jumps 60%

Kestra Medical Technologies (KMTS) reported Q1 2027 revenue growth of 60% but saw increased operating expenses and net loss. The company raised its full-year guidance to $141M, expecting 48% growth. Gross margins expanded for 11 consecutive quarters, with confidence in reaching mid-70% margins. R&D spend increased significantly due to a late-stage project but is expected to normalize. Management attributed growth to prescription volume, in-network mix, and field team expansion.

yahoo.com3 min
SEP 14
$KMTSHigh

Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results KIRKLAND, Wash., September 14, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today reported

SEC EDGAR 8-K2 min